Loading...
Loading...
India's famotidine imports from UNITED STATES total $121.0K across 125 shipments from 15 foreign suppliers. SSS Pharmacy Inc leads with $30.9K in import value; the top 5 suppliers together control 74.7% of this origin. Leading Indian buyers include AUROBINDO PHARMA LTD. This corridor reflects India's pharmaceutical import demand for famotidine โ a diversified sourcing base with multiple active suppliers from UNITED STATES.

SSS Pharmacy Inc is the leading Famotidine supplier from UNITED STATES to India, with import value of $30.9K across 2 shipments. The top 5 suppliers โ SSS Pharmacy Inc, ESPEE BIOPHARMA & FINECHEM LLC, ENDO, AMNEAL PHARMACEUTICALS OF LLC, ENDO PHARMACEUTICALS SOLUTIONS INC. โ collectively account for 74.7% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | SSS Pharmacy Inc | $30.9K | 2 | 25.5% |
| 2 | ESPEE BIOPHARMA & FINECHEM LLC | $28.2K | 5 | 23.3% |
| 3 | ENDO | $12.0K | 2 | 9.9% |
| 4 | AMNEAL PHARMACEUTICALS OF LLC | $10.6K | 3 | 8.8% |
| 5 | ENDO PHARMACEUTICALS SOLUTIONS INC. | $8.8K | 2 | 7.2% |
| 6 | RAFF & HALL PHARMACY | $7.1K | 2 | 5.9% |
| 7 | REGIONAL PHARMACY | $3.9K | 2 | 3.2% |
| 8 | AMSTERDAM PHARMA (APTEKA RX INC.) | $2.9K | 4 | 2.4% |
| 9 | EPIC PHARMA LLC | $2.1K | 2 | 1.7% |
| 10 | BILCARE GCS INC. | $2.0K | 1 | 1.7% |
| 11 | BIONPHARMA,INC. | $2.0K | 1 | 1.7% |
| 12 | M S NEW LIFE MEDICALS USA INC | $2.0K | 1 | 1.7% |
| 13 | NOVITIUM PHARMA LLC | $1.9K | 55 | 1.5% |
| 14 | NEWLIFE MEDICALS (USA). INC | $1.6K | 3 | 1.3% |
| 15 | GOOD HEALTH PHARMA SUPPLIES | $1.1K | 1 | 0.9% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | AUROBINDO PHARMA LTD | $31.7K | 10 | 26.2% |
| 2 | CENTAUR PHARMACEUTICALS PRIVATE LIMITED | $16.4K | 2 | 13.6% |
| 3 | PAR FORMULATIONS PRIVATE LIMITED |
UNITED STATES โ India trade corridor intelligence
As of April 2026, the United States to India shipping corridor remains efficient, with average sea transit times of approximately 30 days and air transit times around 7 days. Major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are operating at standard capacity, with no significant congestion reported. Freight rates have stabilized, and the Indian Rupee (INR) to U.S. Dollar exchange rate remains favorable for importers.
The Indian government's Production-Linked Incentive (PLI) scheme aims to boost domestic manufacturing and reduce import dependency. While this policy encourages local production, it may impact the volume of finished formulation imports, including Famotidine. Import substitution policies are being evaluated to balance domestic industry growth with the need for imported pharmaceuticals.
India and the United States share a strong trade relationship, with ongoing negotiations to enhance cooperation in the pharmaceutical sector. Mutual recognition of Good Manufacturing Practices (GMP) and efforts to streamline regulatory processes are facilitating smoother trade. These bilateral efforts aim to ensure the availability of high-quality pharmaceuticals in India while supporting domestic industry growth.
| $12.0K |
| 3 |
| 9.9% |
| 4 | AXIS CLINICALS LIMITED | $10.8K | 3 | 8.9% |
| 5 | AMNEAL PHARMACEUTICALS PRIVATE LIMITED | $10.6K | 3 | 8.8% |
| 6 | MAIVA PHARMA PRIVATE LIMITED | $7.3K | 4 | 6.0% |
| 7 | ALEMBIC PHARMACEUTICALS LIMITED | $6.9K | 1 | 5.7% |
| 8 | CLIANTHA RESEARCH LIMITED | $4.9K | 2 | 4.0% |
| 9 | COPMED PHARMACEUTICALS PRIVATE LIMITED | $3.9K | 2 | 3.2% |
| 10 | CALLIDUS RESEARCH LABORATORIES PRIVATE LIMITED | $2.8K | 2 | 2.3% |
| 11 | NOVITIUM LABS PRIVATE LIMITED | $2.2K | 56 | 1.8% |
| 12 | MILAN LABORATORIES (INDIA) PRIVATE LIMITED | $2.0K | 1 | 1.7% |
| 13 | NUWILL RESEARCH AND INNOVATIONS PRIVATE LIMITED | $2.0K | 1 | 1.7% |
| 14 | RUBICON RESEARCH PRIVATE LIMITED | $2.0K | 1 | 1.7% |
| 15 | IPCA LABORATORIES LIMITED | $1.6K | 3 | 1.3% |
The landed cost for importing Famotidine formulations from the United States to India includes the following components:
The total landed duty percentage is approximately 32.2% of the CIF value.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing Famotidine into India requires compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations. Importers must obtain a valid Drug Import License from the Directorate General of Foreign Trade (DGFT). The product must be registered with CDSCO, which involves submitting Form CT-20/40/41, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Free Sale Certificate, and stability data. The registration process typically takes 6 to 12 months, depending on the completeness of the application and the regulatory workload. For Famotidine formulations under HS Code 30049039, specific requirements include demonstrating compliance with the Indian Pharmacopoeia standards and providing evidence of safety and efficacy.
Imported Famotidine formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to ensure product integrity in India's climate. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported products. Failure to meet these requirements can result in delays, rejections, or destruction of the goods.
Between 2024 and 2026, the Indian government has implemented several regulatory updates affecting pharmaceutical imports. The Production-Linked Incentive (PLI) scheme has been expanded to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements with the United States have been strengthened, facilitating smoother trade and mutual recognition of Good Manufacturing Practices (GMP). These changes aim to balance the promotion of domestic industry with the need for high-quality imported pharmaceuticals.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Famotidine formulations to meet the demand for branded and patented products not manufactured domestically. Specific dosage forms, such as injectables or extended-release tablets, may not be produced locally. Despite a robust domestic pharmaceutical industry, certain formulations are imported to fulfill market needs. The market size for Famotidine formulations in India is substantial, with imports contributing significantly to the total consumption.
The import duty structure for Famotidine formulations under HS Code 30049039 includes a Basic Customs Duty (BCD) of 10%, a Social Welfare Surcharge (SWS) of 10% on the BCD, and an Integrated Goods and Services Tax (IGST) of 12%. This results in a total landed duty of approximately 32.2% on the CIF (Cost, Insurance, and Freight) value. Exemptions may apply under specific trade agreements or for certain product categories.
India sources Famotidine formulations from the United States due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. While other suppliers like China and Germany also export Famotidine formulations to India, the United States maintains a competitive advantage in terms of product innovation and regulatory compliance. The U.S. share in India's Famotidine import market is significant, reflecting strong trade relations and mutual trust in pharmaceutical quality.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Famotidine formulations from the United States due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Certain formulations, such as extended-release tablets or specific combinations, may not be produced domestically, necessitating imports to meet market demand.
Compared to other origins like China and Germany, the United States offers a competitive advantage in terms of product innovation, quality assurance, and regulatory compliance. U.S. manufacturers adhere to stringent Good Manufacturing Practices (GMP), ensuring high-quality products that meet international standards. This commitment to quality makes U.S. Famotidine formulations a preferred choice for Indian importers.
Indian importers face several supply chain risks when sourcing Famotidine formulations from the United States, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to manufacturing issues or logistical challenges. To mitigate these risks, importers should diversify their supplier base, monitor currency exchange rates, stay updated on regulatory changes, and maintain robust quality assurance processes.
Import license checklist, document requirements, quality testing, and compliance
SECTION:
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Famotidine suppliers from UNITED STATES to India include SSS Pharmacy Inc, ESPEE BIOPHARMA & FINECHEM LLC, ENDO. The leading supplier is SSS Pharmacy Inc with import value of $30.9K USD across 2 shipments. India imported Famotidine worth $121.0K USD from UNITED STATES in total across 125 shipments.
India imported Famotidine worth $121.0K USD from UNITED STATES across 125 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Famotidine sourced from UNITED STATES include AUROBINDO PHARMA LTD, CENTAUR PHARMACEUTICALS PRIVATE LIMITED, PAR FORMULATIONS PRIVATE LIMITED. The largest buyer is AUROBINDO PHARMA LTD with $31.7K in imports across 10 shipments.
The total value of Famotidine imports from UNITED STATES to India is $121.0K USD, across 125 shipments and 15 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
125 Verified Shipments
15 suppliers, 15 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists